Janus kinase

Internal medicine

Immunology

Ruxolitinib

Psoriatic arthritis

Arthritis

Rheumatoid arthritis

Cytokine

Tofacitinib

Bone marrow

Myelofibrosis

Cancer research

Clinical trial

Medicine

BioDrugs

Cytokines, many of which signal through the JAK–STAT (Janus kinase–Signal Transducers and Activators of Transcription) pathway, play a central role in the pathogenesis of inflammatory and autoimmune diseases. Currently three JAK inhibitors have been approved for clinical use in USA and/or Europe: tofacitinib for rheumatoid arthritis, psoriatic arthritis and ulcerative colitis, baricitinib for rheumatoid arthritis, and ruxolitinib for myeloproliferative neoplasms. The clinical JAK inhibitors target multiple JAKs at high potency and current research has focused on more selective JAK inhibitors, almost a dozen of which currently are being evaluated in clinical trials. In this narrative review, we summarize the status of the pan-JAK and selective JAK inhibitors approved or in clinical trials, and discuss the rationale for selective targeting of JAKs in inflammatory and autoimmune diseases.

Selective JAKinibs: Prospects in Inflammatory and Autoimmune Diseases